News

The market is forward-looking, but investors who earn better-than-average returns often look even further into the future and identify opportunities that are currently being overlooked. That means

Florida-based wealth advisory J. L. Bainbridge & Co. sold 119,376 shares of Biogen (NASDAQ:BIIB) during the third quarter for an estimated $16.1 million.

In a quarterly disclosure filed with the

What's even better than a solid, reliable dividend stock? A solid, reliable, high-yield dividend stock. One that is trading at attractive levels is even more preferable. Excellent dividend payers

Burns Matteson Capital Management, LLC reported a new stake in UnitedHealth Group (NYSE:UNH), acquiring 8,017 shares in the third quarter of 2025, an estimated $2.77 million trade as of the end of

On October 16, 2025, ASSET PLANNING SERVICES INC /LA/ /ADV disclosed in an SEC filing that it sold out of Pfizer(NYSE:PFE), with an estimated $2.66 million trade.

According to a Securities and

On Thursday, QSM Asset Management disclosed a significant buy of Pfizer (NYSE:PFE), adding shares worth an estimated $6.8 million in the third quarter.

QSM Asset Management increased its position in

Investing in pharmaceutical stocks can carry risks. It's not always clear which drugs will be successful and turn into blockbusters for their respective businesses. As a result, it can take years

Over the past decade, pharmaceutical maker Pfizer (NYSE: PFE) has severely lagged the market. Dividends reinvested aside, the stock is in the red over this period, while the S&P 500 is up by almost

The idea of steady money flowing in, year after year, should appeal to nearly everyone. This isn't an unrealistic dream; investing in stocks that pay reliable dividends can make it a reality.

And

On October 15, 2025, Davenport & Co LLC disclosed a purchase of 155,551 shares of UnitedHealth Group (UNH) for the period ended Q3 2025, an estimated $47.04 million trade.

An SEC filing dated

CCLA Investment Management disclosed a purchase of 66,275 shares of Abbott Laboratories (NYSE:ABT) , estimated at ~$8.70 million based on the quarterly average price, in its SEC filing for the

There are significant advantages to holding shares of companies for a long time as opposed to, say, day trading. The buy-and-hold approach is simpler, doesn't leave investors at the mercy of

Graphene Investments SAS fully exited its position in Centene Corporation (NYSE:CNC) during the third quarter, selling approximately 55,600 shares in a transaction estimated at ~$3.02 million as of

On October 2 and October 3, 2025, Sheila A. Denton, EVP & General Counsel of Incyte (NASDAQ:INCY), executed an option exercise and immediately sold 4,100 shares of common stock, as disclosed in this

One way to earn above-average market returns -- which isn't always easy -- is to invest in companies that have lagged the market but are likely to recover over the long run. As the basic investing

Turning $10,000 into $50,000 in about five years would require a compound annual growth rate (CAGR) of almost 38%. That's an extremely tough task for any corporation, but can Merck (NYSE: MRK), a

On October 10, 2025, Sarasin & Partners LLP disclosed a significant reduction in its UnitedHealth Group (NYSE:UNH) stake, selling 465,744 shares in an estimated $140.86 million trade.

Sarasin &amp

Dividend stocks never go out of style, but they might be even more worthy of consideration right now because some evidence suggests that troubles lie ahead. The government shutdown and remaining

The 6.7% dividend yield on offer from Pfizer (NYSE: PFE) is both a sign of opportunity and risk. A lot will happen over the next five years that will determine if that dividend is sustainable. But

UnitedHealth (NYSE: UNH) shares are up significantly since I upgraded the stock to a buy rating.

*Stock prices used were the afternoon prices of Oct. 6, 2025. The video was published on Oct. 8

There are several compelling reasons to invest in pharmaceutical companies, especially when the economy isn't doing well. Since they belong to a defensive industry, drugmakers tend to perform better

As President Donald Trump's escalating tariff policies threaten to raise costs across global supply chains, one pharmaceutical giant is taking steps to protect its bottom line. On Sept. 30, Pfizer

Shares in Viking Therapeutics (NASDAQ: VKTX) were up more than 16% in the week to Thursday at 1 pm. The move comes after the announcement of another acquisition of a small-cap biopharmaceutical

Wilsey Asset Management disclosed the purchase of Pfizer shares valued at an estimated $2.9 million during the third quarter, according to an SEC filing released Wednesday.

According to a filing

Carolina Wealth Advisors, LLC disclosed in an Oct. 7, 2025, U.S. Securities and Exchange Commission filing that it sold 38,267 AbbVie shares for the quarter ended Sept. 30, 2025, an estimated $7.79